argenx SE

argenx SE is a biotechnology company that focuses on developing therapies to treat autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod, a monoclonal antibody that is currently in Phase III clinical trials for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Additionally, efgartigimod is also in Phase II/III clinical trials for the treatment of bullous pemphigoid and idiopathic inflammatory myopathy, and in pre-clinical study for ENHANZE SC.

argenx SE is also developing other immunology innovation programs, such as cusatuzumab for hematological cancer and high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. Additionally, the company has strategic partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreements with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH.

argenx SE was founded in 2008 and is headquartered in Breda, the Netherlands. The company has over 800 employees and has offices in Belgium, Germany, France, Switzerland, and the United States. It has a market capitalization of over $8.5 billion and is listed on the Nasdaq Global Select Market. argenx SE is dedicated to developing innovative therapies to address unmet medical needs in autoimmune diseases and cancer.